Metal-Oxo Photo-oxidants, Photochemistry and Photophysics of trans-[Os^(VI)(tmc)(O)_2]^(2+)(tmc = 1,4,8,11-tetramethyl-1,4,8,11-tetra-azacyclotetradecane) and trans-[Os^(VI)(CN)_4(O)_2]^(2-)

trans-[Os^(VI)(tmc)(O)_2]^(2+)(tmc = 1,4,8,11-tetramethyl-1,4,8,11-tetra-azacyclotetradecane) and trans-[Os^(VI)(CN)_4(O)_2]^(2-) are emissive in the solid state and in fluid solutions at room temperature (τ~ 1.0–1.5 µs); the (^3)E_g state of trans-[Os^(VI)(tmc)(O)_2]^(2+) is a powerful one-electron oxidant {[Os^(VI)(O)_2]^(2+) + e^– → [Os^V (O)_2]+, E^0_f > 2.0 V vs. normal hydrogen electrode} in aqueous solution, reacting with PPh3 and ((PhCH_2)_2)S to give O=PPh_3 and ((PhCH_2)_2)S=O, respectively

Electronic spectra and photophysics of platinum(II) complexes with α-diimine ligands. Mixed complexes with halide ligands

Emission properties have been studied for a series of compounds of the formula (L_2)PtC1_2, where L_2 is N,N,N',N'-tetramethylethylenediamine, 2,2'-bipyridine (bpy), 4,4'-Me_2bpy, 5,5'-Me_2bpy, 4,4'-(t-Bu)_2bpy, 3,3'-(CH_3OCO)_2bpy, and 1,10-phenanthroline, and also for the compound Pt(bpy)I_2. Most of them exhibit orange to red luminescence from a triplet ligand-field (^3LF) state, both as solids and in glassy solution. These emissions are very broad (fwhm 2300-3400 cm^(-1) at 10 K) and structureless and are strongly Stokes-shifted from absorption. The two exceptions are the solid "red" form of Pt(bpy)Cl_2, which exhibits a relatively narrow (fwhm 1050 cm^(-1) at 10 K), vibronically structured (Δν ~ 1500 cm^-1)) red emission, and Pt(3,3'-(CH_3OCO)_2bpy)Cl_2, which exhibits a broad (fwhm 2500 cm^(-1) at 10 K) but structured (Δν ~1300 cm^(-1)) orange emission. Both of these emissions are assigned to triplet metal-to-ligand charge-transfer (^3MLCT) excited states. For the former compound, a linear-chain structure has destabilized a dσ*(d_(z^2)) level, yielding a dσ* → π*(bpy) state as the lowest energy excited state, while for the latter, the strongly electron-withdrawing substituents have stabilized a bpy π* level, yielding a dσ* → π*(bpy) state as the lowest energy excited state. The relative energies of the various types of excited states, including ligand 3_(ππ*) states, are discussed in detail. The crystal structures of Pt(5,5'-Me_2bpy)Cl_2 (monoclinic Cc, Z = 4, a = 13.413(7) Å, b = 9.063(4) Å, c = 12.261(9) Å, 0 = 121.71(6)') and Pt(3,3'-(CH_3OCO)_2bpy)Cl_2 (triclinic P1, Z = 2, a = 7.288(2) Å, b = 9.932(3) Å, c = 11.881(5) Å, α = 98.04(3)°, β = 103.56(3)°, γ = 106.54(3)°) are reported

Shares in the EMCA : the time is ripe for true no par value shares in the EU, and the 2nd directive is not an obstacle

The most interesting proposal in the draft European Model Companies Act ( EMCA) concerning shares and the focus of this Article is the recommendation to introduce true no par value shares, as they have been in use in the US for many years and were introduced in Australia, New Zealand but also Finland more recently. Contrary to what has often been assumed, the 2nd EU Company Law Directive does not preclude no par value shares. There is nothing in the wording of the Directive to suggest otherwise, and the reference in the Directive to shares without a nominal value is a reference to Belgian law, which has allowed true no par value shares in all but name since at least 1913. EU member states could therefore introduce such shares even for public companies. True no par value shares offer a far more flexible framework in case of capital increases or mergers, but since under a no par value system there is no link between par value and shareholder rights, additional disclosure about these rights might be warranted under a no par value system. Traditional par value shares offer no protection to creditors, shareholders or other stakeholders, so that their abolition should not be mourned. The threat of new share issues at an unacceptably high discount is more efficiently countered by disclosure and shareholder decision rights

Papillary Adenocarcinoma of Rete Testis Mimics Inflammatory Lump: A Case Report

We presented a rare extratesticular neoplasm, papillary adenocarcinoma of rete testis, which manifested variable symptoms and mimicked most frequently seen benign extratesticular lesions. Due to its rarity, the treatment is therefore uncertain. Our patient's clinical manifestations mimicked an inflammatory lump and underwent radical orchiectomy after pathological report had been confirmed. Unlike other reports, our patient survives and has a good outcome. No definite predictor and tumor marker can be used to define the prognosis. Early diagnosis and surgical treatment may have a good outcome

The Guardian, April 9, 1982

Eight page issue of The Guardian, the official student-run newspaper for Wright State University. The Guardian has been published regularly since March of 1965.https://corescholar.libraries.wright.edu/guardian/1998/thumbnail.jp

Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation

Development of anticancer drugs is challenging. Indeed, much research effort has been spent in the development of new drugs to improve clinical outcomes with minimal toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles as a carrier platform. We encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and compared using an in vivo neuroblastoma (N2A) model. We showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of drug delivery into tumor tissue and subsequently more effective antitumor activity. This specific design of a chemotherapeutic agent using nanotechnology is important in the development of a safe and effective drug in cancer therapy.published_or_final_versio

Interdisciplinary intervention decreases cognitive impairment for older Taiwanese with hip fracture: 2‐year follow‐up

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/101759/1/gps3945.pd

Electronic spectra and photophysics of platinum(II) complexes with α-diimine ligands. Mixed complexes with halide ligands

Emission properties have been studied for a series of compounds of the formula (L_2)PtC1_2, where L_2 is N,N,N',N'-tetramethylethylenediamine, 2,2'-bipyridine (bpy), 4,4'-Me_2bpy, 5,5'-Me_2bpy, 4,4'-(t-Bu)_2bpy, 3,3'-(CH_3OCO)_2bpy, and 1,10-phenanthroline, and also for the compound Pt(bpy)I_2. Most of them exhibit orange to red luminescence from a triplet ligand-field (^3LF) state, both as solids and in glassy solution. These emissions are very broad (fwhm 2300-3400 cm^(-1) at 10 K) and structureless and are strongly Stokes-shifted from absorption. The two exceptions are the solid "red" form of Pt(bpy)Cl_2, which exhibits a relatively narrow (fwhm 1050 cm^(-1) at 10 K), vibronically structured (Δν ~ 1500 cm^-1)) red emission, and Pt(3,3'-(CH_3OCO)_2bpy)Cl_2, which exhibits a broad (fwhm 2500 cm^(-1) at 10 K) but structured (Δν ~1300 cm^(-1)) orange emission. Both of these emissions are assigned to triplet metal-to-ligand charge-transfer (^3MLCT) excited states. For the former compound, a linear-chain structure has destabilized a dσ*(d_(z^2)) level, yielding a dσ* → π*(bpy) state as the lowest energy excited state, while for the latter, the strongly electron-withdrawing substituents have stabilized a bpy π* level, yielding a dσ* → π*(bpy) state as the lowest energy excited state. The relative energies of the various types of excited states, including ligand 3_(ππ*) states, are discussed in detail. The crystal structures of Pt(5,5'-Me_2bpy)Cl_2 (monoclinic Cc, Z = 4, a = 13.413(7) Å, b = 9.063(4) Å, c = 12.261(9) Å, 0 = 121.71(6)') and Pt(3,3'-(CH_3OCO)_2bpy)Cl_2 (triclinic P1, Z = 2, a = 7.288(2) Å, b = 9.932(3) Å, c = 11.881(5) Å, α = 98.04(3)°, β = 103.56(3)°, γ = 106.54(3)°) are reported

A General Phase Matching Condition for Quantum Searching Algorithm

A general consideration on the phase rotations in quantum searching algorithm is taken in this work. As four phase rotations on the initial state, the marked states, and the states orthogonal to them are taken account, we deduce a phase matching condition for a successful search. The optimal options for these phase are obtained consequently.Comment: 3 pages, 3 figure